Altimmune (ALT) Short term Debt (2012 - 2022)
Altimmune (ALT) posted quarterly Short term Debt of $4.3 million for Q1 2022, down 29.23% quarter-over-quarter from $6.1 million in Q4 2021.
Powered by 
Analysis
Altimmune (ALT) Short term Debt (2012 - 2022) Analysis & Trends
Altimmune (ALT) has reported Short term Debt for 6 consecutive years, with $4.3 million the latest figure, recorded in Q1 2022.
- In Q1 2022, Short term Debt changed N/A year-over-year to $4.3 million; the TTM figure through Mar 2022 stood at $4.3 million (changed N/A YoY), while the FY2021 annual figure was $6.1 million, changed N/A from the prior year.
- Short term Debt retreated to $4.3 million in Q1 2022 per ALT's latest filing, from $6.1 million in the prior quarter.
- Across five years, Short term Debt topped out at $6.1 million in Q4 2021 and bottomed at $4.3 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 4.31 Mn |
| Dec 31, 2021 | 6.09 Mn |
| Jun 30, 2015 | 249,491.00 |
| Mar 31, 2015 | 498,203.00 |
| Dec 31, 2014 | 746,146.00 |
| Jun 30, 2014 | 999,996.00 |
| Mar 31, 2014 | 999,996.00 |
| Dec 31, 2013 | 1.09 Mn |
| Sep 30, 2013 | 999,996.00 |
| Jun 30, 2013 | 1.17 Mn |
| Mar 31, 2013 | 1.33 Mn |
| Dec 31, 2012 | 1.33 Mn |
| Sep 30, 2012 | 1.21 Mn |
| Jun 30, 2012 | 454,548.00 |
| Mar 31, 2012 | 857,808.00 |